MiMedx Director Acquires $185K in Stock Through Annual Grant Program
MiMedx Group director Tiffany Olson received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share.
Rhea-AI Filing Summary
MiMedx Group director Tiffany Olson received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Olson's direct ownership increased to 57,597 shares.
Key details of the grant:
- Transaction was filed as an exempt grant under Rule 16b-3
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Grant is part of standard non-employee director compensation
- Transaction was executed through attorney-in-fact William F. Hulse
This Form 4 filing represents routine board compensation and indicates continued alignment between director and shareholder interests through equity-based compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 28,609 shares
Grant/Award
1 txn
Insider
Olson Tiffany
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 28,609 | $6.47 | $185K |
Holdings After Transaction:
Common Stock — 57,597 shares (Direct)
Footnotes (1)
- F1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
FAQ
What is the vesting period for MDXG's director stock grants in 2025?
The restricted stock grant for MDXG non-employee directors vests upon the earlier of 12 months from the grant date or the next annual meeting of shareholders, as disclosed in the Form 4 filing.
Was MDXG Director Tiffany Olson's stock acquisition made under Rule 10b5-1?
No, the stock acquisition was not made under Rule 10b5-1. The Form 4 indicates this was an annual restricted stock grant to non-employee directors that is exempt under Rule 16b-3.
AI-generated analysis. How Rhea-AI works. Not financial advice.